Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 7/20 | 0.63 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.46 |
| ▸ | TYK2 | P29597 | 1/20 | 0.45 |
| ▸ | IKBKB | O14920 | 6/20 | 0.44 |
| ▸ | CHUK | O15111 | 5/20 | 0.44 |
| ▸ | CDK9 | P50750 | 4/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.42 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.41 |
| ▸ | CCNK | O75909 | 1/20 | 0.40 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30009346 | 0.93 | JAK1 (0.65) | JAK1PIK3C3TYK2IKBKBCHUK | |
| SCHEMBL30009522 | 0.88 | JAK1 (0.50) | JAK1PIK3C3IKBKBCHUKCDK9 | |
| SCHEMBL30009242 | 0.84 | JAK1 (0.58) | JAK1PIK3C3TYK2IKBKBCHUK | |
| SCHEMBL30009178 | 0.82 | JAK1 (0.53) | JAK1PIK3C3CDK9CCNT1 | |
| SCHEMBL20930187 | 0.78 | JAK1 (1.00) | JAK1 | |
| SCHEMBL30009838 | 0.75 | JAK1 (0.67) | JAK1CDK9CCNT1 | |
| SCHEMBL30009345 | 0.74 | JAK1 (0.60) | JAK1PIK3C3TYK2IKBKBCHUK | |
| SCHEMBL30009608 | 0.72 | JAK1 (0.59) | JAK1TYK2IKBKBCHUKCDK9 | |
| SCHEMBL20918691 | 0.72 | JAK1 (1.00) | JAK1 | |
| SCHEMBL30356202 | 0.72 | JAK1 (1.00) | JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | claimed |
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | MAP3K20, MAP3K15, MAP3K1 | JAK1 83/4885PIK3C3 288/4885TYK2 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.